Cedars-Sinais KronosRx Uses AI to Revolutionize Drug Safety
cedars-sinai.org
|
Contributed by: Kate Gamble
Summary
Cedars-Sinai has received over $5 million to develop KronosRx, an innovative platform utilizing artificial intelligence to improve drug safety by predicting adverse drug reactions through 'patient avatars.' This technology aims to enhance pharmacovigilance and optimize clinical trials, addressing significant issues of drug toxicity that often lead to trial failures and post-market withdrawals. By simulating patient responses using extensive genetic and health data, KronosRx could effectively identify safety concerns before drugs reach the market. This advancement has significant implications for healthcare professionals, as it promises to reduce harmful side effects and improve patient outcomes through more personalized medication approaches.
